David Auerbach is the newly appointed Head of Business Projects – Oncology R&D Business Planning & Operations at AstraZeneca

July 21, 2020

David Auerbach is the newly appointed Head of Business Projects within the Oncology R&D Business Planning & Operations organization at AstraZeneca. He directly supports the Executive Vice President of Oncology R&D and works closely with the leadership team to deliver strategic and operational priorities and drive the business.

He previously was Head of Business Planning & Operations within Early Oncology R&D. Prior to this role, he managed complex projects and alliances at MedImmune. Prior to MedImmune, he worked in life sciences management consulting at Capgemini Consulting, assay development at Teva Pharmaceuticals and HIV research at the National Institutes of Health. He has a dual MBA and MS in Biotechnology graduate degree from Johns Hopkins University.

AstraZeneca (LSE/STO/NYSE: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of diseases in three therapy areas – Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca.

The following two tabs change content below.
Over the past 8 years, Chris has grown BioBuzz into a respected brand that is recognized for its community building, networking events and news stories about the local biotech industry. In addition, he runs a Recruiting and Marketing Agency that helps companies attract top talent through a blended model that combines employer branding and marketing services together with a high powered recruiting solution.

Leave a Reply

Your email address will not be published.

This site uses Akismet to reduce spam. Learn how your comment data is processed.